Latest / Pricing Power Podcast with Fexingo: How Businesses Set Prices, Raise Margins, and Win Customers / How Pharmaceutical Companies Price Drugs at Launch
Transcript
- Lucas: So a few weeks ago, the FDA approved a one-time gene therapy for sickle cell disease, and the manufacturer set the wholesale price at over two million dollars per patient. Luna: Two million dollars. That's more than most people will earn in a lifetime. How do you even justify a number like that? Lucas: That's exactly what we're digging into today. The launch price of a new drug isn't just a number pulled from a hat. It's the result of a complex calculation that balances R&D costs, the size of the patient population, and what the market will bear. Luna: And that calculation has to satisfy investors, insurers, and the public. It's a tough needle to thread. Lucas: It is. And the interesting thing is, the traditional way of pricing drugs, which was essentially cost plus a margin, is giving way to something called value-based pricing. That's where the price is linked to the outcomes the drug delivers, like fewer hospitalizations or longer survival. Luna: So for sickle cell, instead of saying 'this cost us a billion to develop, so we price it at X', they're saying 'this saves the healthcare system millions over a patient's lifetime, so we're charging a fraction of that.' Lucas: Precisely. And it's a logic that has real traction in the industry, but it also creates these enormous sticker prices that are hard for people to swallow. Lucas: Let's break down the numbers. The sickle cell gene therapy, Casgevy, priced at around two point two million dollars. The manufacturer, Vertex Pharmaceuticals, points to the fact that sickle cell patients often face repeated crises, frequent hospital stays, and a shortened lifespan. The lifetime cost of care for a severe patient can easily exceed four million dollars. Luna: So from that angle, the therapy is actually cheaper than the status quo over a lifetime. But the problem is, a two million dollar bill comes due all at once, whereas the ongoing costs are spread out over years. Lucas: Right, and that's a cash-flow problem for insurers and for government programs like Medicaid, which covers many sickle cell patients. They may see the long-term savings, but their budgets are annual, and a two million dollar claim is a shock to the system. Luna: So we're seeing these companies offer outcomes-based contracts, where they give rebates if the therapy doesn't work as promised. That's a way to de-risk the upfront cost. Lucas: It is, and we've seen that with other gene therapies like Zolgensma, that's the spinal muscular atrophy treatment priced at over two million dollars. Novartis set up installment plans and outcomes-based rebates to ease the sticker shock. Luna: It's almost like financing a car, but for a cure. Lucas: Exactly. And that analogy is actually pretty useful. The price has to be high enough to recoup a decade of research and failed trials, but it has to be framed in a way that payers can say yes to. Lucas: But here's where it gets even more interesting. The patient population for sickle cell in the United States is around one hundred thousand people, and only a fraction will be eligible for this gene therapy. So the company can't rely on volume. They have to get the price right per patient. Luna: That's a classic orphan drug dilemma. Small population, high development cost, so the per-patient price has to be massive just to break even. Lucas: And that's not just for rare diseases. Even for more common conditions, the launch price is increasingly set by looking at the 'budget impact' on the healthcare system. If a drug costs too much relative to the number of eligible patients, insurers will push back and require prior authorization or step therapy, which can strangle a product's adoption. Luna: So the pricing team has to think like a market entry strategist, not just a finance person. They're anticipating how payers will react and setting a price that's just below the threshold of outright refusal. Lucas: That's the art of the launch price. And it's notoriously difficult to get right. Set it too high and you risk public outrage and political intervention. Set it too low and you leave money on the table and signal a lack of confidence in your product. Luna: And we've seen the political intervention side. The Inflation Reduction Act allows Medicare to negotiate prices for certain high-cost drugs starting in 2026. The first list included several blockbusters like Eliquis and Jardiance, and the negotiated prices came in significantly lower than the list prices. Lucas: That's a game changer. For years, list prices were just a starting point, with rebates and discounts flowing to middlemen. Now, the government is directly setting a price, and that changes the calculus for new drugs coming to market. Lucas: So if you're pricing a drug today, you have to model in the possibility that within nine years, Medicare might be negotiating a price on your product. And that negotiation will be based on the drug's clinical benefit and cost-effectiveness, not just your R&D costs. Luna: So the launch price is effectively the floor for future negotiations. Set it lower now, and you'll have a lower ceiling later. Lucas: Exactly. And that's why we're seeing more companies adopt value-based pricing frameworks from day one. They want to anchor the price to outcomes so that when the negotiation happens, they can defend the price with clinical data. Lucas: We should also talk about the role of ICER, the Institute for Clinical and Economic Review. They do cost-effectiveness analyses and often propose a 'value-based price' that's far below the manufacturer's list price. Those reports get a lot of attention and can shape public opinion and payer decisions. Luna: Right, so it's not just the government and PBMs. There's an entire ecosystem of stakeholders weighing in on what a drug should cost. Lucas: And at the end of the day, the manufacturer has to weave all these threads together into a single number that launches the product. It's a high-stakes decision that can make or break the drug's commercial success. Luna: So what would you say is the single biggest factor in setting that launch price today? Is it the science, the competition, or the politics? Lucas: I'd say it's the payer landscape. You can have the best drug in the world, but if the price isn't aligned with what insurers and Medicare are willing to pay, it's not going to reach patients. And that's where the pressure is mounting. Lucas: And on that note, we do these conversations every week, and we love doing them without any ads. If you've gotten something out of this, and you want to support that ad-free mission, the link is buy me a coffee dot com slash fexingo. No pressure, but it does help us keep the lights on. Luna: Yeah, we really appreciate it. It's a small way to keep this independent and focused on the topics we care about. Lucas: So back to the launch price. One thing we haven't touched on is the global dimension. In Europe, several countries use health technology assessments to determine a price based on cost-effectiveness thresholds. That means the US launch price often ends up being two or three times higher than what's accepted in the UK or France. Luna: So manufacturers are effectively pricing to the US market and accepting lower prices elsewhere. It's a form of price discrimination based on each country's willingness to pay. Lucas: Exactly. And that's why you'll see companies sometimes launch a drug in Germany first, because they have a more flexible pricing system, and use that to build real-world evidence that can support higher prices elsewhere. Lucas: It's a chess game, and the launch price is the opening move. As more gene therapies and personalized medicines come to market, these pricing decisions are only going to get more complex and more visible. Luna: And with the Inflation Reduction Act negotiations ramping up, we're going to see a lot more scrutiny on how these numbers are derived. Lucas: Definitely. Next time you see a headline about a billion-dollar drug, you'll know it's not just a number. It's a carefully calculated bet on patient outcomes, market dynamics, and the future of healthcare finance. Luna: That's a good place to leave it. Thanks for joining us, and we'll see you next time.